Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early clearance for R-B, Adams

This article was originally published in The Tan Sheet

Executive Summary

Slough, U.K.-based Reckitt Benckiser on Jan. 8 announced the receipt of an early termination of the waiting period under the Hart-Scott-Rodino Act regarding its offer to purchase all outstanding shares of Adams Respiratory Therapeutics' stock. Through its wholly owned subsidiary Twickenham, Reckitt, a household cleaning, health and personal care product firm, made an offer in December to purchase all Chester, N.J.-based Adams' outstanding stock for $60 per share (1"The Tan Sheet" Dec. 17, 2007, p. 5)...

You may also be interested in...

Reckitt Benckiser Looks Overseas To Double Adams’ Revenue

Reckitt Benckiser should meet its goal of doubling Adams Respiratory Therapeutics' revenues by launching the firms' OTC cough and congestion products overseas and introducing new products being developed by Adams in the United States, analysts and Reckitt executives say

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts